4.1 Article

Hemodialysis and biotransformation of erythrocyte epoxy fatty acids in peripheral tissue

Journal

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.plefa.2022.102453

Keywords

Hemodialysis; Eicosanoids; Lipidomics; Oxylipins; Erythrocyte; Arterio-venous; Biotransformation

Funding

  1. Deutsche Forschungsgemeinschaft (DFG) [FCL 435/13-1]
  2. Open Access Publication Fund Charite Universitatsmedizin Berlin

Ask authors/readers for more resources

This study found differences in erythrocyte epoxy fatty acid profiles in arterial and venous blood in patients with renal failure who underwent hemodialysis treatment. The LOX pathway metabolites in erythrocytes showed arteriovenous differences after dialysis, indicating potential deleterious effects on circulation.
Cardiovascular disease is the leading cause of mortality in patients with renal failure. Red blood cells (RBCs) are potential reservoirs for epoxy fatty acids (oxylipins) that regulate cardiovascular function. Hemoglobin exhibits pseudo-lipoxygenase activity in vitro. We previously assessed the impact of single hemodialysis (HD) treatment on RBC epoxy fatty acids status in circulating arterial blood and found that eicosanoids in oxygenated RBCs could be particularly vulnerable in chronic kidney disease and hemodialysis. The purpose of the present study was to evaluate the differences of RBC epoxy fatty acids profiles in arterial and venous blood in vivo (AV differences) from patients treated by HD treatment. We collected arterial and venous blood samples in upper limbs from 12 end-stage renal disease (ESRD) patients (age 72 +/- 12 years) before and after HD treatment. We measured oxylipins derived from cytochrome P450 (CYP) monooxygenase and lipoxygenase (LOX)/CYP omega/(omega-1)-hydroxylase pathways in RBCs by LC-MS/MS tandem mass spectrometry. Our data demonstrate arteriovenous differences in LOX pathway metabolites in RBCs after dialysis, including numerous hydroxyeicosatetraenoic acids (HETEs), hydroxydocosahexaenoic acids (HDHAs) and hydroxyeicosapentaenoic acids (HEPEs). We detected more pronounced changes in free metabolites in RBCs after HD, as compared with the total RBC compartment. Hemodialysis treatment did not affect the majority of CYP and CYP omega/(omega-1)-hydroxylase products in RBCs. Our data indicate that erythro-metabolites of the LOX pathway are influenced by renal-replacement therapies, which could have deleterious effects in the circulation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available